Who is sponsoring NCT03754608?

NCT03754608 is sponsored by Yale University.

What drugs are being tested in NCT03754608?

Interventions in NCT03754608: MRI including cf-MRI, DTI, ASL and CVR..

What condition does NCT03754608 study?

NCT03754608 studies Small Vessel Disease of Diabetes Mellitus.

Is NCT03754608 still recruiting?

NCT03754608 is currently completed. Last updated 19 April 2021.

Last reviewed 2021-04-19 · How we verify

NCT03754608

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Validating Imaging Biomarkers of Small Vessel Disease in Diabetic Individuals Using Advanced MRI Techniques.

Completed Last updated 19 April 2021

What this trial tests

trial testing MRI including cf-MRI, DTI, ASL and CVR. in Small Vessel Disease of Diabetes Mellitus in 63 participants. Completed in 31 August 2020.

Timeline

7 November 2018

Primary endpoint
31 August 2020

31 August 2020

Quick facts

Lead sponsor	Yale University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	63
Start date	7 November 2018
Primary completion	31 August 2020
Estimated completion	31 August 2020
Sites	1 location across United States

Drugs / interventions tested

MRI including cf-MRI, DTI, ASL and CVR.

Conditions studied

Small Vessel Disease of Diabetes Mellitus — all drugs for Small Vessel Disease of Diabetes Mellitus →

Sponsor

Yale University

Who can join

Adults 55 to 90, any sex, with Small Vessel Disease of Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To develop a set of biomarkers for imaging of small vessel disease in diabetic individuals using advanced MRI techniques. With this the investigators want to document progression of disease both radiologically and clinically.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03754608 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 19 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03754608.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing